Whole lung lavage: Treating pulmonary alveolar proteinosis at the time of COVID pandemic

Katherine Jean Powers a, Vasanthi Avadhanula b, Purvesh R. Patel c, Pralay Kumar Sarkar c, Pedro Piedra b, Neda Zarrin-Khameh d, e, *

a Department of Anesthesiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA
b Department of Molecular Virology & Microbiology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA
c Department of Pulmonary, Critical Care and Sleep Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA
d Department of Pathology & Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA
e Ben Taub Hospital, 1504 Taub Loop, Houston, TX, 77030, USA

ARTICLE INFO

Keywords:
Pulmonary alveolar proteinosis
COVID-19
Whole pulmonary lavage
Viral load

ABSTRACT

Pulmonary alveolar proteinosis (PAP) is a rare syndrome due to increased production or decreased clearance of surfactant in alveoli and terminal bronchi that cause hypoxemic respiratory insufficiency. Here we present a patient with PAP whose disease was exacerbated by superimposed COVID-19 pneumonia. He underwent whole lung lavage (WLL). Evaluation of the viral count of the first and the last lavage of the left lung showed viral load in the alveolar space dropped by approximately 10-folds, however the magnitude of the viral load was substantial in both lavage samples. Whole pulmonary lavage may be used as a treatment option on patients with PAP even when the disease is exacerbated by COVID-19 pneumonia.

1. Introduction

Pulmonary alveolar proteinosis (PAP) is a rare syndrome characterized by abnormal accumulation of surfactant in alveoli and terminal airways resulting in hypoxemic respiratory insufficiency [1,2], and defects in alveolar macrophage- and neutrophil-mediated host defense [3]. It is divided into disorders of surfactant production and surfactant clearance [4]. Disorders of production include pulmonary surfactant metabolic dysfunction disorders caused by mutations in genes encoding surfactant proteins or genes encoding proteins involved in production of surfactant. Disorders in clearance can be further divided into primary PAP caused by disruption of granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling and secondary PAP caused by another condition that disrupts alveolar macrophage surfactant clearance.

2. Case report

The patient is a 29-year-old man with a past medical history of PAP diagnosed in 2018. He had no other medical problems and endorsed working in construction for 12 years, mainly brick work with some exposure to cement and dust.

In 2018, he presented with complain of a 15-days of lip/ear cyanosis, shortness of breath (SOB), cough productive of yellow

---

* Corresponding author. Department of Pathology & Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
E-mail addresses: Katherine.powers@bcm.edu (K.J. Powers), avadhana@bcm.edu (V. Avadhanula), Purvesh.Patel@bcm.edu (P.R. Patel), Pralay.Sarkar@bcm.edu (P.K. Sarkar), ppiedra@bcm.edu (P. Piedra), Neda.Zarrin-Khameh@bcm.edu (N. Zarrin-Khameh).

https://doi.org/10.1016/j.rmcr.2022.101707
Received 8 December 2021; Received in revised form 5 July 2022; Accepted 6 July 2022
Available online 14 July 2022
2213-0071/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
sputum, and maculopapular rash on his back and neck. He was found to be hypoxic to 72% on room air and admitted to the medical intensive care unit. CT scan on admission was concerning for PAP with ground-glass opacities with inter-septal thickening. Two months prior to his admission, he had been hospitalized at another hospital and underwent a lung biopsy that confirmed PAP. There, he received a right lung lavage with 18L normal saline, which was aborted as he developed hypoxemia (Table 1).

Extensive work up in our hospital was negative for HIV, acid fast bacilli (AFB) and various fungal infections. His ANA, P-ANCA and C-ANCA were negative. GM-CSF autoantibody was positive and STAT5 phosphorylation index test was abnormal.

During his stay, he underwent a left lung lavage with 24L of saline, followed by a right lung lavage with 25L of saline 7 days later. He was discharged on room air, with inhaled GM-CSF for 12 weeks. He was instructed to return to pulmonary clinic for serial pulmonary function tests (PFT). He was also referred to the genetics and rheumatology clinics to assess for familial autoimmune PAP.

He was lost to follow up until March 2020 when he presented to the emergency department (ED) with SOB, cough with green phlegm, myalgias, and fever. His chest x-ray showed patchy infiltrates consistent with pneumonia and CT scan of the chest showed diffuse ground glass opacities and consolidation with interlobular thickening. He was found to be COVID negative and discharged with a course of doxycycline.

He then presented to the ED in December 2020 with complaints of SOB, headache, and fever for one week. He was found to be hypoxic as low as 55% and admitted to MICU on 40L/min high nasal flow cannula (HFNC) at 60% inspired oxygen fraction (FiO₂). He was found to be COVID+ and started on Remdesivir and Dexamethasone with cefepime and azithromycin to cover for superimposed bacterial pneumonia. Due to his history of PAP, he was started on GM-CSF nebulizers twice a day.

Expectorated sputum was sent for culture, periodic acid Schiff (PAS) stain, and acid fast bacilli (AFB). Bronchoscopy was deferred due to COVID positivity and severe hypoxia. Sputum showed granular PAS+, fungal hyphae suggestive of candida, and rare alveolar macrophages. AFB cultures were negative three times.

Over the next 4 days his oxygen requirement decreased to 15L/min HFNC on 100% FiO₂ and he was transferred to the intensive medical unit. Six days into his admission, the patient reported that he felt better but chest imaging did not change and his oxygen requirements remained the same. Ten days into his admission, his oxygen requirements were unchanged and chest CT scan showed diffuse ground glass opacities and septal thickening consistent with his known history of PAP (Fig. 1).

Due to his inability to wean from HFNC, ongoing sputum production, and completion of a full course of Remdesivir and Dexamethasone, it was favored that his underlying pathology was more likely a PAP flare than his known COVID infection. The patient remained persistently positive for COVID on PCR throughout his entire admission, so the decision was made to use another course of

---

Table 1

| Date     | 06/2018 | 07/2018 | 10/2018 | 05/2019 |
|----------|---------|---------|---------|---------|
| FVC (L)  | 314     | 4.45    | 4.88    |
| FVC (%)  | 68      | 97      | 107     |
| FEV₁ (L) | 2.44    | 3.85    | 4.09    |
| FEV₁ (%) | 63      | 101     | 108     |
| TLC (L)  | 4.52    | 5.75    | 6.37    |
| TLC (%)  | 79      | 101     | 112     |
| DLco     | 9.17 (adj) | 24.91 (unadj) | 25.74 (unadj) |
| DLco (%) | 27      | 74      | 77      |
| 6MWD (meters) | 240 m; nadir 90% on 3L/min O₂ | 330 m; nadir 90% on 3L/min O₂ | 445 m; required 3L/min O₂ | 500 m; nadir 97% on room air |

FVC: forced vital capacity, FEV1: forced expiratory volume in 1 s, TLC: total lung capacity, DLCO: diffuse capacity of the lung for carbon monoxide, 6MWD: 6-min walking distance.

---

**Table 1**

This table shows the trend of pulmonary function tests in the patient.

---

Fig. 1. CT scan showed diffuse ground glass opacities and septal thickening consistent with his known history of PAP.
Remdesivir to hopefully lower his viral load in anticipation of a bronchoscopy and possible WLL. Unfortunately, his oxygen saturations worsened and his $O_2$ requirements increased. He was transferred back to the MICU on HFNC to 40L on 100% FiO$_2$ with worsening chest x-ray findings.

After a heated and long discussion in the consensus conference compose of physicians from infectious disease, pulmonology, critical care, surgery and pathology regarding this atypical course of COVID pneumonia, the cause of his ongoing symptoms and worsening oxygen requirements was thought to be much more likely from a PAP flare. Thus, the decision was made to undergo a bronchoscopy and perform a WLL with cardiothoracic surgery for extracorporeal membrane oxygenation backup. This was explained to the patient and his family and he consented for the procedure. Sixteen days into his admission, we performed a WLL on the patient’s left lung with 18L normal saline (NS) (Fig. 2). The following day, WLL was performed on the right lung with 18L NS. The patient was successfully extubated the following day and was discharged 3 days later on 3L/min nasal canula (NC) $O_2$ at rest and 4L/min with exertion. He was started one nebulized GM-CSF for a total of 24 weeks, 1 week on and 1 week off.

The first and last specimens from the left WLL were tested with real-time reverse transcriptase polymerase chain reaction diagnostic panel that targets the nucleocapsid (N) gene (N1 and N2) and host extraction control ribonuclease P (RNase-P) gene. The viral load in
first BAL specimen with the highest concentration of proteinosis had a high viral load of 8.6 \log_{10} \text{copies/mL} of N1. The viral load reduced to 7.7 \log_{10} \text{copies/mL} of N1 in the last lavage specimen obtained, which was also reflected by a decrease in the level of proteinosis. This suggested that between the lavage samples the viral load in the alveolar space dropped by approximately 10-folds, however the magnitude of the viral load was substantial in both lavage samples.

His chest x-ray examinations through his hospital stay and after discharge show his gradual improvement (Fig. 3). As the patient improved gradually, in March 2022, he was gradually weaned off GM-CSF. On his most visit on 4/26/22, the patient reports he has no residual symptoms.

3. Discussion

PAP is a rare disease characterized by interalveolar accumulation of surfactant impairing gas exchange and resulting in progressive respiratory insufficiency [1]. PAP has three distinct clinical forms: primary, secondary and congenital [1,2]. Primary or idiopathic PAP accounts for 90% of PAP case. Secondary PAP occurs as a consequence of various underlying diseases [5]. Congenital PAP is a heterogenous collection of disorders caused by homozygous mutation of the genes encoding surfactant protein (SP)–B, SP-C and the ABCA3 transporter or by the absence of granulocyte/macrophage colony-stimulating factor (GM-CSF) receptor [6].

The prevalence of PAP has recently been determined to be 6.87 ± 0.33 per million in the general population and it affects men and women similarly [7]. Autoimmune PAP represented 89.9% of cases and had a minimum incidence and prevalence of 0.49 and 6.2 per million, respectively [8].

Autoimmune PAP generally presents as progressive dyspnea of insidious onset unless secondary infection is also present, in which it presents with fever, cough and rarely hemoptysis. Chest CT typically shows bilateral patchy or diffuse air-space consolidation or hazy ground-glass opacity similar to pulmonary edema but without other features of the left heart failure. WLL is the current gold standard of care, however, GM-CSF augmentation strategies are also used in autoimmune PAP [9].

Management of PAP patients infected with COVID-19 is challenging. The present case demonstrates that WLL may benefit the patient as it not only removes the excessive surfactant, but also decreases the viral load.

References

[1] J.F. Seymour, J.J. Presneill, Pulmonary alveolar proteinosis: progress in the first 44 years, Am. J. Respir. Crit. Care Med. 166 (2) (2002) 215–235.
[2] B.C. Trapnell, J.A. Whirsett, K. Nakata, Pulmonary alveolar proteinosis, N. Engl. J. Med. 349 (26) (2003) 2527–2539.
[3] B. Carey B, B.C. Trapnell, The molecular basis of pulmonary alveolar proteinosis, Clin. Immunol. 135 (2) (2010) 223–235.
[4] T. Suzuki, B.C. Trapnell, Pulmonary alveolar proteinosis syndrome, Clin. Chest Med. 37 (3) (2016) 431–440.
[5] M.S. Kavuru, T.L. Bonfield, M.J. Thompson, Pulmonary alveolar proteinosis, in: R.J. Mason, V.C. Broaddus, J.F. Murray, J.A. Nadel JA (Eds.), Textbook of Pulmonary Medicine, Elsevier, Philadelphia, 2006, pp. 1716–1734.
[6] J.A. Whitsett, S.E. Wert, B.C. Trapnell, Genetic disorders influencing lung formation and function at birth, Hum. Mol. Genet. 13 (2004) R207–R215.
[7] C. McCarthy, R. Avetitsyan, B.C. Carey, Prevalence and healthcare burden of pulmonary alveolar proteinosis, Orphanet J. Rare Dis. 13 (1) (2018) 129.
[8] Y. Inoue, B.C. Trapnell, R. Tazawa, Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan, Am. J. Respir. Crit. Care Med. 177 (7) (2008) 752–762.
[9] B.C. Trapnell, M. Luisetti, Pulmonary alveolar proteinosis syndrome, in: Murray and Nadel’s Textbook of Respiratory Medicine, Elsevier, 2016, pp. 1260–1274.